Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-κB p65

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 28, Issue 4, 2008, Pages 415-420

  Fan, Heng ^a   Chen, Rui ^a   Shen, Lin ^a   Lv, Jianfang ^a   Xiong, Pengcheng ^a   Shou, Zhexing ^a   Zhuang, Xiong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colitis; Interleukin 10 (IL 10); Interleukin 2 (IL 2); Nuclear factor B p65; Oxymatrine

Indexed keywords

ALKALOID; INTERLEUKIN 10; INTERLEUKIN 2; OXYMATRINE; QUINOLIZINE DERIVATIVE; RELA PROTEIN, RAT; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COLITIS; COLON; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; RAT; SOPHORA; SPRAGUE DAWLEY RAT;

ALKALOIDS; ANIMALS; COLITIS; COLON; DOWN-REGULATION; INTERLEUKIN-10; INTERLEUKIN-2; MALE; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; SOPHORA; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID;

EID: 49749092619     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-008-0409-x     Document Type: Article

References (36)

1. Podolsky D K. Inflammatory bowel disease. N Engl J Med, 2002,347(6):417-429
2. Hecht G A. Inflammatory Bowel disease-Live transmission. N Engl J Med, 2008,358(5):528-530
3. Frank D N, St Anand A L, Feldman R A et al. Molecu-lar-phylogenetic characterization of microbial community imbalances in human inflammatory bowel disease. Proc Natl Acad Sci USA, 2007,104(34):13780-13785
4. Baumgart D C, Sandborn W J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007,369(9573):1641-57
5. Loftus E V Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology, 2004,126(6):1504-1517
6. Fan H, Qiu M Y, Mei J J et al. Effects of Four Regulating intestines Prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis, World J Gastroenterol, 2005,11(31):4800-4806
7. Baumgart D C, Carding S R. Inflammatory bowel disease: cause and immunobiology. Lancet, 2007,369(9573):1627-1640
8. Ito H, Hirotani T, Yamamoto M et al. Kishimoto T.Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T cell apoptosis1m a murmemodel of Crohn's disease. J Gastroenterol, 2002,37(Suppl4):56-61
9. Schmidt C, Marth T, Wittig B M et al. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology, 2002,70(3):177-183
10. Lochner M, Forster I. Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology, 2002,70(3):164-169
11. Baeuerle P A, Baltimore D. NF-κB: ten years after. Cell, 1996,87(1):13-20
12. Sen P, Wallet M A, Yi Z et al. Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood. 2007,109(2):653-60
13. Neurath M F, Fuss I, Schürmann G et al. Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel dis-ease. Ann NY Acad Sci, 1998,859(17):149-159
14. Neurath M F, Pettersson S, Meyer zum Büschenfelde K H et al. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med, 1996,2(9):998-1004
15. Zheng P, Niu F L, Liu W Z et al. Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats. World J Gastroenterol, 2005,11(31):4912-4915
16. Morris G P, Beck P L, Herridge M S et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology, 1989,96(3):795-803
17. Dikopoulos N, Schmid R M, Bachem M et al. Bile synthesis in rat models of inflammatory bowel diseases. Eur J Clin Invest, 2007,37(3):222-230
18. Wallace J L, MacNaughton W K, Morris G P et al. Inhibition of leukot-riene synthesis markedly accelerates healing in a rat model of in-flammatory bowel disease. Gastroenterology, 1989,96(1):29-36
19. Ten Hove T, Corbaz A, Amitai H et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production. Gastroenterology, 2001,121(6):1372-1379
20. Te Velde A A, Verstege M I, Hommes D W. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis, 2006,12(10):995-999
21. Abad C, Martinez C, Juarranz M G et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology, 2003,124(4):961-971
22. Iijima H, Neurath M F, Nagaishi T et al. Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med, 2004,199(4):471-482
23. Hwang E S, Hong J H, Glimcher L H. IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J Exp Med, 2005,202(9):1289-1300
24. Mullin G E, Lazenby A J. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology, 1992,102(5):1620-1627
25. Rennick D M, Fort M M. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflamma-tion. Am J Physiol Gastrointest Liver Physiol, 2000,278(6):G829-G833
26. Fedorak R N, Gangl A, Elson C O et al. Recombinant human inter-leukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology, 2000,119(6):1473-1482
27. Baeuerle P A, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol, 1994,12:141-179
28. Huang WC, Chen J J, Chen C C. c-Src-dependent tyrosine phosphory-lation of IKKbeta is involved in tumor necrosis fac-tor-alpha-induced intercellular adhesion molecule-1 expression. J Biol Chem, 2003,278(11):9944-9952
29. Wang P, Wu P, Siegel M I et al. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem, 1995,270(16):9558-9563
30. Abreu M T, Vora P, Faure E et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterialimmatory gene expression in response to bacterial lipopolysaccharide. J Immunol, 2001,167(3):1609-1616
31. Tak P P, Firestein G S. NF-KB: a key role in inflammatory diseases. J Clin Invest, 2001,107(1):7-11
32. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kap-paB inflammatory bowel disease. Gut, 1998, 42(4):477-484
33. Matsunaga T, Hokari S, Koyama I et al. NF-kappaB activation in endothelial cells treated with oxidized high-density lipoprotein. Biochem Biophys Res Commun, 2003,303(1):313-319
34. Zaninoni A, Imperiali F G, Pasquini C et al. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol, 2003,31(3):185-190
35. Chen Y M, Tu C J, Hung K Y et al. Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappaB down-regulation. Br J Pharmacol, 2003, 138(3): 950-958
36. Kis A, Yellon D M, Baxter G F. Role of nuclear factor-kappaB activa-tion in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol, 2003,138(3):894-900